AnaptysBio

Yahoo Finance • 3 days ago

Biggest stock movers today: UUUU, FLY, and more

[Financial chart with moving up arrow graph in stock market on blue color background] Stock futures and Treasury yields slipped early Tuesday, the last trading day of September, as investors weighed the potential impact of a looming feder... Full story

Yahoo Finance • 3 days ago

AnaptysBio splits operations into two companies

[Divorce law and inheritance separation concept. Hand separate saving money, finance, home loan, debt return with piggybank and wood house. Bank business investment. Man separate stack coin on table] M.photostock/iStock via Getty Images A... Full story

Yahoo Finance • 3 days ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from... Full story

Yahoo Finance • 3 days ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB0... Full story

Yahoo Finance • last month

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 2 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for... Full story

Yahoo Finance • 4 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment periodFavorable safety and tolerability, particularly when compared to standard of care biologi... Full story

Yahoo Finance • 4 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated d... Full story

Yahoo Finance • 5 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June Initial Phase 2 data... Full story

Yahoo Finance • 6 months ago

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the... Full story

Yahoo Finance • 6 months ago

Anaptys Announces Stock Repurchase Plan

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a... Full story

Yahoo Finance • 7 months ago

Anaptys Announces Participation in March Investor Conferences

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 7 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for rosnilimab in RA i... Full story

Yahoo Finance • 8 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDA... Full story

Yahoo Finance • 8 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line... Full story

Yahoo Finance • 8 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 8 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised... Full story

Yahoo Finance • 2 years ago

13 Best Short Squeeze Stocks To Buy Now

In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story

Yahoo Finance • 2 years ago

AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares

AnaptysBio Inc (NASDAQ:ANAB), a biotechnology company engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, has reported an insider sale according to a recent SEC filing. The insid... Full story

Yahoo Finance • 2 years ago

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2... Full story